How a cancer therapy #antibody target was developed and taken to the clinic
515H7 mAb, a new monoclonal antibody which blocks SDF-1/CXCR4 signalling for cancer therapy has been explored by Dr Christine Klinguer-Hamour and colleagues at the Centre dâ€™Immunologie Pierre Fabre, and resulted in two mAbs in phase 1 clinical trials.
At the 2011 European Antibody Congress Dr Klinguer-Hamour presented a case study taking the mAb from generation to in vitro studies, binding inhibition assays, and finally clinical studies in animals.
Do you want to see the results ? Click on the video-link below to see the complete presentation!
Do you want to find out more?